Protara Therapeutics Inc. (TARA)
| Bid | 3.4 |
| Market Cap | 132.9M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -44.6M |
| EPS (ttm) | -2.17 |
| PE Ratio (ttm) | -1.59 |
| Forward PE | -1.66 |
| Analyst | Buy |
| Ask | 3.63 |
| Volume | 396,757 |
| Avg. Volume (20D) | 347,785 |
| Open | 3.52 |
| Previous Close | 3.50 |
| Day's Range | 3.41 - 3.60 |
| 52-Week Range | 1.59 - 10.48 |
| Beta | 1.59 |
About TARA
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failur...
Analyst Forecast
According to 5 analyst ratings, the average rating for TARA stock is "Buy." The 12-month stock price forecast is $21.5, which is an increase of 524.09% from the latest price.
Stock Forecasts
1 month ago · seekingalpha.com
Protara Therapeutics: Speculative Buy On Promising TARA-002 Trial ResultsTARA's leading candidate is TARA-002, which so far looks like a promising immune-stimulating therapy derived from OK-432 (Picibanil). Their recent Phase 2 ADVANCED-2 trial also showed favorable result...